EuCorVac-19
EuCorVac-19 je kandidátem na vakcínu proti nemoci COVID-19 vyvinutý společností EuBiologics Co.[1][2][3][4] EuBiologics Co. zahájila klinické testy 23. února 2021.[5]
Odkazy editovat
Reference editovat
V tomto článku byl použit překlad textu z článku EuCorVac-19 na anglické Wikipedii.
- ↑ EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea. www.businesswire.com [online]. 2021-01-21 [cit. 2021-11-16]. Dostupné online. (anglicky)
- ↑ EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine ‘EuCOVAC-19’. Businesskorea [online]. 2021-01-21 [cit. 2021-11-16]. Dostupné online. (korejsky)
- ↑ EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea. eubiologics.com [online]. [cit. 2021-11-16]. Dostupné online. (anglicky)
- ↑ NEWS, ABS-CBN. Firm looks to build vaccine manufacturing plant in PH. ABS-CBN News [online]. 2021-04-12 [cit. 2021-11-16]. Dostupné online. (anglicky)
- ↑ EUBIOLOGICS CO.,LTD. A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults. [s.l.]: [s.n.] Dostupné online. Submitted: March 3, 2021.